Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.

Miettinen TP, Peltier J, Härtlova A, Gierliński M, Jansen VM, Trost M, Björklund M.

EMBO J. 2018 May 15;37(10). pii: e98359. doi: 10.15252/embj.201798359. Epub 2018 Apr 18.

2.

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2018 Mar 26. doi: 10.1158/1078-0432.CCR-17-2904. [Epub ahead of print]

PMID:
29581135
3.

From biology to therapy: Improvements of therapeutic options in Lung cancer.

Formisano L, Jansen VM, Marciano R, Bianco R.

Anticancer Agents Med Chem. 2017 Sep 12. doi: 10.2174/1871520617666170912123416. [Epub ahead of print]

PMID:
28901258
4.

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.

Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL.

Clin Cancer Res. 2017 Oct 15;23(20):6138-6150. doi: 10.1158/1078-0432.CCR-17-1232. Epub 2017 Jul 27.

PMID:
28751448
5.

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL.

Cancer Res. 2017 May 1;77(9):2488-2499. doi: 10.1158/0008-5472.CAN-16-2653. Epub 2017 Mar 1.

6.

Is There a Future for AKT Inhibitors in the Treatment of Cancer?

Jansen VM, Mayer IA, Arteaga CL.

Clin Cancer Res. 2016 Jun 1;22(11):2599-601. doi: 10.1158/1078-0432.CCR-16-0100. Epub 2016 Mar 15.

7.

Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL.

Cancer Res. 2016 Jan 15;76(2):440-52. doi: 10.1158/0008-5472.CAN-15-1640-T. Epub 2015 Dec 16.

8.

Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL.

Cancer Res. 2015 Jan 15;75(2):405-14. doi: 10.1158/0008-5472.CAN-14-2475. Epub 2014 Dec 5.

Supplemental Content

Loading ...
Support Center